Compounds & interventions

Tirzepatide

Public Health · covered by 37 outlets this week · tracked since 2026-10-27

Press: 22 mainstream 50 specialist 11 independent outlet-days

What it is

Evidence 9/10 · thoroughly established Uneven · 5–10 by use Signals · regulator warning

Tirzepatide is Eli Lilly's dual GIP and GLP-1 receptor agonist, sold as Mounjaro for type 2 diabetes and Zepbound for weight loss and sleep apnoea. It produced the largest weight loss of any approved drug in trials, around 20 percent, and head-to-head data put it ahead of semaglutide. Coverage follows the same themes as the class (cost, access, muscle loss, stopping) plus counterfeit pens, its use after bariatric surgery, and new indications under study.

The score describes type 2 diabetes (approved 2022), obesity (2023) and obstructive sleep apnoea (2024), each after large trials. Heart-failure and kidney uses are still under study, and long-term follow-up is shorter than semaglutide's.

Evidence by use or claim · 1 preclinical to 10 thoroughly established

  1. Type 2 diabetes10/10 · thoroughly established

    Approved in 2022 after the SURPASS trials.

  2. Obesity and weight management10/10 · thoroughly established

    Approved in 2023 after the SURMOUNT trials.

  3. Obstructive sleep apnoea with obesity9/10 · thoroughly established

    Approved in 2024 after two phase 3 trials.

  4. Cardiovascular outcomes7/10 · established for some uses

    SURPASS-CVOT (2025) showed it was no worse than dulaglutide; no placebo-controlled outcome trial.

  5. Heart failure with preserved ejection fraction6/10 · mixed or limited trials

    One positive trial (SUMMIT, 2024) in people with obesity.

  6. Chronic kidney disease5/10 · mixed or limited trials

    Kidney signals in diabetes trials; dedicated trials under way.

  • RegulatorUS label carries a boxed warning for thyroid C-cell tumours, as for the rest of the class; contraindicated with a history of medullary thyroid cancer. source
  • TrialGastrointestinal effects rise with dose and drove most discontinuations in trials; rare severe pancreatitis has been reported, and the UK regulator updated its guidance in 2026. source
  • RegulatorCzech and other European regulators have flagged counterfeit Mounjaro pens found abroad.
  • MarketCompounded tirzepatide spread during the 2022 to 2024 shortage; the FDA declared the shortage over in October 2024 and compounded supply is being wound down. source

This week · The FDA required a label warning on all GLP-1 drugs, including tirzepatide, about NAION, a rare optic nerve condition, after an analysis of 126 trials.

Written by the Alivewire editors from the coverage below, 3d ago; rated 2d ago. Not medical advice; how the ratings work.

Coverage